Brief: Palatin's Vyleesi Licensee Fosun Pharma Reports First Commercial Sale In China
08/08/2023 13:35
Aug 8 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN'S VYLEESI® LICENSEE FOSUN PHARMA REPORTS FIRST
COMMERCIAL SALE IN CHINA AND SOUTH KOREAN LICENSEE KWANGDONG
PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 CLINICAL STUDY
* PALATIN TECHNOLOGIES INC - DATA EXPECTED LATER THIS YEAR
* PALATIN TECHNOLOGIES INC - SUPPORTS SUBMISSION TO KOREAN
MINISTRY OF FOOD & DRUG SAFETY (MFDS) FOR MARKETING APPROVAL
Source text for Eikon: ID:nPnhprRJa
Further company coverage: PTN.A
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity